MCID: PNC013
MIFTS: 48

Pancreatic Ductal Carcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Ductal Carcinoma

MalaCards integrated aliases for Pancreatic Ductal Carcinoma:

Name: Pancreatic Ductal Carcinoma 12 15
Carcinoma, Pancreatic Ductal 44 71
Malignant Neoplasm of Duct of Wirsung 12
Carcinoma Pancreatic Ductal 54
Pancreatic Duct Cancer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3587
ICD9CM 34 157.3
MeSH 44 D021441
SNOMED-CT 67 93939009
ICD10 32 C25.3
UMLS 71 C0153461 C0887833

Summaries for Pancreatic Ductal Carcinoma

Disease Ontology : 12 A pancreatic carcinoma located in the pancreatic duct.

MalaCards based summary : Pancreatic Ductal Carcinoma, also known as carcinoma, pancreatic ductal, is related to acinar cell carcinoma and ovarian serous carcinoma. An important gene associated with Pancreatic Ductal Carcinoma is SMAD4 (SMAD Family Member 4), and among its related pathways/superpathways are Innate Immune System and Metabolism of proteins. The drugs Axitinib and Hyaluronic acid have been mentioned in the context of this disorder. Affiliated tissues include pancreatic duct, pancreas and myeloid, and related phenotypes are Reduced mammosphere formation and cellular

Related Diseases for Pancreatic Ductal Carcinoma

Diseases related to Pancreatic Ductal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 485)
# Related Disease Score Top Affiliating Genes
1 acinar cell carcinoma 30.5 TP53 SMAD4 KRT7
2 ovarian serous carcinoma 30.4 TP53 KRT7 CDH1
3 benign mesothelioma 30.3 MSLN KRT7 KRT20 CDKN2A
4 skin squamous cell carcinoma 30.3 TP53 ERBB2 CDKN2A
5 cystadenoma 30.3 MUC6 MUC5AC MUC1 KRT7 KRT20
6 ovarian serous cystadenocarcinoma 30.3 VEGFA TP53 ERBB2
7 wilms tumor 1 30.0 TP53 MYC MUC1 KRT7 ERBB2
8 pancreatic ductal adenocarcinoma 30.0 VEGFA TP53 STAT3 SMAD4 MYC MUC1
9 retinitis pigmentosa 11 30.0 TP53 MYC ERBB2 EGFR CDKN2A
10 cystadenocarcinoma 29.9 VEGFA TP53 MUC5AC MUC2 MUC1 KRT7
11 tubular adenocarcinoma 29.9 MUC5AC MUC2 MUC1 KRT7 KRT20 ERBB2
12 adenoma 29.8 TP53 SMAD4 MUC6 MUC5AC MUC1 KRT7
13 pancreatic adenocarcinoma 29.7 VEGFA TYMP TP53 STAT3 SMAD4 ERBB2
14 breast ductal carcinoma 29.5 VEGFA TP53 SMAD4 MUC5AC MUC1 KRT7
15 mucoepidermoid carcinoma 29.5 TP53 MUC5AC MUC2 MUC1 KRT7 ERBB2
16 in situ carcinoma 29.4 TP53 MYC MUC1 ERBB2 EGFR EGF
17 glioblastoma 29.4 VEGFA TP53 STAT3 MYC ERBB2 EGFR
18 adenocarcinoma 29.3 VEGFA TYMP TP53 STAT3 SMAD4 MYC
19 squamous cell carcinoma 28.8 VEGFA TP53 STAT3 SMAD4 MYC MUC1
20 lung cancer susceptibility 3 28.5 VEGFA TP53 STAT3 SMAD4 MYC MUC5AC
21 gastric cancer 28.1 VEGFA TYMP TP53 STAT3 SMAD4 MYC
22 pancreatic cancer 27.9 VEGFA TYMP TP53 TGM2 STAT3 SMAD4
23 colorectal cancer 27.3 VEGFA TYMP TP53 TGM2 STAT3 SMAD4
24 pancreatic adenosquamous carcinoma 11.2
25 scrotum paget's disease 10.5 MUC1 KRT7
26 colloid carcinoma of the pancreas 10.5 MUC5AC MUC1
27 anal gland adenocarcinoma 10.5 MUC5AC KRT7
28 anus adenocarcinoma 10.5 MUC5AC KRT7
29 intrahepatic biliary papillomatosis 10.5 MUC5AC MUC1
30 cervical mucinous adenocarcinoma 10.5 MUC6 KRT7
31 urethral villous adenoma 10.5 KRT7 KRT20
32 nodular hidradenoma 10.5 MUC1 KRT7
33 cervical basaloid squamous cell carcinoma 10.5 KRT7 CDKN2A
34 bladder benign neoplasm 10.5 KRT7 KRT20
35 middle ear adenoma 10.4 MUC1 KRT7
36 inverted transitional papilloma 10.4 KRT7 CDKN2A
37 nephrogenic adenoma of urinary bladder 10.4 KRT7 KRT20
38 anal canal paget's disease 10.4 KRT7 CDKN2A
39 cap polyposis 10.4 MUC5AC MUC2
40 small cell carcinoma of the bladder 10.4 KRT7 KRT20
41 pediatric angiosarcoma 10.4 VEGFA TP53
42 pancreatic serous cystadenocarcinoma 10.4 KRT7 KRT20
43 pancreatic foamy gland adenocarcinoma 10.4 TP53 MUC1 KRT7
44 breast hemangioma 10.4 TP53 KRT7
45 chronic ethmoiditis 10.4 MUC6 MUC5AC MUC1
46 bile duct mucoepidermoid carcinoma 10.4 MUC5AC MUC1 KRT7
47 mucinous tubular and spindle renal cell carcinoma 10.4 MUC6 MUC1 KRT7
48 cervical adenoid cystic carcinoma 10.4 KRT7 CDKN2A
49 bile duct mucinous adenocarcinoma 10.4 TP53 MUC5AC MUC1
50 cystadenofibroma 10.4 TP53 MUC1 KRT7

Graphical network of the top 20 diseases related to Pancreatic Ductal Carcinoma:



Diseases related to Pancreatic Ductal Carcinoma

Symptoms & Phenotypes for Pancreatic Ductal Carcinoma

GenomeRNAi Phenotypes related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CDH1 EGFR KRT7 MUC5AC MYC SMAD4

MGI Mouse Phenotypes related to Pancreatic Ductal Carcinoma:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.37 CDH1 CDKN2A CXCL12 EGFR ERBB2 KRT7
2 cardiovascular system MP:0005385 10.31 CDH1 CDKN2A CXCL12 EGFR ERBB2 MUC2
3 homeostasis/metabolism MP:0005376 10.3 CDH1 CDKN2A EGFR ERBB2 KRT7 MUC2
4 digestive/alimentary MP:0005381 10.29 CDH1 CDKN2A EGF EGFR ERBB2 MUC2
5 immune system MP:0005387 10.28 CDH1 CDKN2A CXCL12 EGF EGFR MUC2
6 endocrine/exocrine gland MP:0005379 10.26 CDH1 CDKN2A EGF EGFR ERBB2 MUC2
7 embryo MP:0005380 10.15 CDH1 CDKN2A EGFR ERBB2 MYC SMAD4
8 integument MP:0010771 10.1 CDH1 CDKN2A EGF EGFR ERBB2 MYC
9 neoplasm MP:0002006 10 CDH1 CDKN2A EGFR ERBB2 MUC2 MYC
10 liver/biliary system MP:0005370 9.97 CDKN2A CXCL12 EGFR MYC SMAD4 STAT3
11 muscle MP:0005369 9.97 CDKN2A CXCL12 EGFR ERBB2 MYC SMAD4
12 no phenotypic analysis MP:0003012 9.76 CDH1 CDKN2A CXCL12 EGFR MYC TGM2
13 normal MP:0002873 9.7 CDH1 CXCL12 EGF EGFR ERBB2 MSLN
14 reproductive system MP:0005389 9.36 CDH1 CDKN2A CXCL12 EGF EGFR ERBB2

Drugs & Therapeutics for Pancreatic Ductal Carcinoma

Drugs for Pancreatic Ductal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 53)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Axitinib Approved, Investigational Phase 3 319460-85-0 6450551
2
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
3 Protein Kinase Inhibitors Phase 3
4
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
5
Pancrelipase Approved, Investigational Phase 1, Phase 2 53608-75-6
6
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
7
Gemcitabine Approved Phase 2 95058-81-4 60750
8
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
9
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
10
Apaziquone Investigational Phase 1, Phase 2 114560-48-4 5813717
11
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
12 topoisomerase I inhibitors Phase 2
13 pancreatin Phase 1, Phase 2
14
Liposomal doxorubicin Phase 2 31703
15 Immunosuppressive Agents Phase 2
16 Albumin-Bound Paclitaxel Phase 2
17 Antimitotic Agents Phase 2
18 Tubulin Modulators Phase 2
19 Immunologic Factors Phase 2
20 Anti-Infective Agents Phase 2
21 Antimetabolites Phase 2
22 Antiviral Agents Phase 2
23 Folfirinox Phase 2
24
Oxaliplatin Approved, Investigational Phase 1 61825-94-3 5310940 9887054 6857599 43805
25
Fluorouracil Approved Phase 1 51-21-8 3385
26
leucovorin Approved Phase 1 58-05-9 6006
27
Levoleucovorin Approved, Investigational Phase 1 68538-85-2 149436
28
Cisplatin Approved Phase 1 15663-27-1 84093 441203 2767
29
Durvalumab Approved, Investigational Phase 1 1428935-60-7
30
Etoposide Approved Phase 1 33419-42-0 36462
31
Carboplatin Approved Phase 1 41575-94-4 10339178 498142 38904
32
Azacitidine Approved, Investigational Phase 1 320-67-2 9444
33
Folic acid Approved, Nutraceutical, Vet_approved Phase 1 59-30-3 6037
34
Tremelimumab Investigational Phase 1 745013-59-6
35 Nutrients Phase 1
36 Protective Agents Phase 1
37 Micronutrients Phase 1
38 Vitamin B Complex Phase 1
39 Hematinics Phase 1
40 Antineoplastic Agents, Immunological Phase 1
41 Trace Elements Phase 1
42 Vitamins Phase 1
43 Folate Phase 1
44 Vitamin B9 Phase 1
45 Calcium, Dietary Phase 1
46 Etoposide phosphate Phase 1
47 Antidotes Phase 1
48 Mitogens Phase 1
49
Calcium Nutraceutical Phase 1 7440-70-2 271
50 Anesthetics

Interventional clinical trials:

(show all 32)
# Name Status NCT ID Phase Drugs
1 A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Completed NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
2 A Randomized, Double-Blind Phase 3 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For The First-Line Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer. Completed NCT00471146 Phase 3 AG-013736;Gemcitabine;Gemcitabine;placebo
3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma Terminated NCT02715804 Phase 3 Placebo;nab-Paclitaxel;Gemcitabine
4 Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer Unknown status NCT02529579 Phase 1, Phase 2 Gemcitabine
5 Phase II Study of Chemotherapy Selection Based on Therapeutic Targets for the Treatment of Advanced Pancreatic Cancer Unknown status NCT01394120 Phase 2 Targeted Therapy Tailored Treatment;Standard Chemotherapy
6 A Phase II, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of the Combination of S-1, Irinotecan and Oxaliplatin (SIRIOX) in Treating Patients With Advanced Inoperable or Metastatic Pancreatic Cancer Unknown status NCT03403101 Phase 2 S1;Oxaliplatin;Irinotecan
7 A PHASE Ib/IIa STUDY OF COMBINATION THERAPY WITH GEMCITABINE AND ATU027 IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA Completed NCT01808638 Phase 1, Phase 2 Atu027 & gemcitabine in lead in safety period;Atu027 & gemcitabine in treatment arm 1;Atu027 & gemcitabine in treatment arm 2
8 A Non-controlled, Single Arm, Open Label, Phase II Study of Intravenous and Intratumoral Administration of ParvOryx in Patients With Metastatic, Inoperable Pancreatic Cancer Completed NCT02653313 Phase 1, Phase 2 Parvovirus H-1 (H-1PV)
9 A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer Completed NCT00902291 Phase 2
10 An Open-Label Phase 2 Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002 Completed NCT01608711 Phase 2
11 A Multicenter, Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) in Subjects With Advanced or Unresectable Pancreatic Ductal Carcinoma Whose Tumors Have Progressed Following Prior Treatment With Gemcitabine and Fluoropyrimidine-Based Chemotherapy Completed NCT01580397 Phase 2 INNO-206
12 Ultrasound-enhanced Uptake of Chemotherapy in Patients With Inoperable Pancreatic Ductal Adenocarcinoma - A Randomized Controlled Trial Recruiting NCT04146441 Phase 2 Chemotherapy
13 Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer Terminated NCT02243007 Phase 2 FOLFIRINOX;Gemcitabine/nab-Paclitaxel;Capecitabine
14 A Multicenter Phase II Trial of Weekly Gemcitabine, Paclitaxel, and Hyperfractionated External Irradiation (63.80 GY) for Locally Advanced Pancreatic Cancer Withdrawn NCT00226746 Phase 2 Paclitaxel and gemcitabine
15 A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Patients With Advanced Solid Tumors. Completed NCT02658214 Phase 1 paclitaxel + carboplatin;carboplatin + etoposide;gemcitabine + carboplatin;nab-paclitaxel (paclitaxel-albumin) + carboplatin;oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid);nab-paclitaxel (paclitaxel-albumin) + gemcitabine;cisplatin + 5-fluorouracil (5FU)
16 A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors Completed NCT01478685 Phase 1 CC-486;Carboplatin;ABI-007
17 A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Adult Patients With Advanced Solid Tumors Recruiting NCT04045496 Phase 1 JAB-3312
18 A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Adult Patients With Advanced Solid Tumors Recruiting NCT04121286 Phase 1 JAB-3312
19 Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas Unknown status NCT02817308
20 To Compare the Influences of Different Methods to Remove the Pancreatic Ductal Adenocarcinoma With the Detection of Circulating Tumor Cells Unknown status NCT02451384
21 A Clinical Validation Study on the Efficacy of MicroRNA-25 Level Detection in Assisting the Diagnosis of Pancreatic Cancer Unknown status NCT03432624
22 An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy Unknown status NCT02310230
23 Endoscopic Retrograde CholangioPancreatography Endomicroscopy Registry Outcomes Database Completed NCT00779688
24 Circulating Tumor Cells Shed in Operative Blood During Pancreatectomy for Pancreatic Cancer is Responsible for Peritoneal Recurrence Completed NCT02150746
25 Continuous Monitoring of Vital Signs in Hospitalized Patients Completed NCT02933307
26 Impact of Nationwide Enhanced Implementation of Best Practices in Pancreatic Cancer Care (PACAP-1): a Multicenter Stepped-wedge Cluster Randomized Controlled Trial Recruiting NCT03513705
27 Comprehensive Molecular Characterization of Advanced Pancreatic Ductal Adenocarcinomas (PDAC) for Better Treatment Selection: A Prospective Study Recruiting NCT02750657
28 Establishing Organoids From Metastatic Pancreatic Cancer Patients, the OPT-I Study Recruiting NCT03500068
29 Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy Recruiting NCT02928081
30 An International Multi-centre Retrospective Cohort Study Investigating Patterns of Cancer Recurrence Following Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma, Ampullary Adenocarcinoma and Distal Bile Duct Cholangiocarcinoma Recruiting NCT04596865
31 A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers Terminated NCT01413451 Early Phase 1 Amatuximab (MORab-009)
32 Role of Adrenomedullin in Early Diagnosis of Pancreatic Cancer in New Onset Diabetes Patients Terminated NCT02456051

Search NIH Clinical Center for Pancreatic Ductal Carcinoma

Inferred drug relations via UMLS 71 / NDF-RT 51 :


gemcitabine
Gemcitabine hydrochloride

Cochrane evidence based reviews: carcinoma, pancreatic ductal

Genetic Tests for Pancreatic Ductal Carcinoma

Anatomical Context for Pancreatic Ductal Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Pancreatic Ductal Carcinoma:

19
Pancreatic Duct

MalaCards organs/tissues related to Pancreatic Ductal Carcinoma:

40
Pancreas, Myeloid, Liver, Lung, Prostate, T Cells, Endothelial

Publications for Pancreatic Ductal Carcinoma

Articles related to Pancreatic Ductal Carcinoma:

(show top 50) (show all 355)
# Title Authors PMID Year
1
Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. 61 54
16951195 2006
2
Intercalated duct cell is starting point in development of pancreatic ductal carcinoma? 54 61
16018800 2005
3
Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. 54 61
15725805 2005
4
The role of chromosome 18 abnormalities in the progression of pancreatic adenocarcinoma. 61 54
15084978 2004
5
MUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine-needle aspiration. 61 54
14681945 2003
6
Expressions of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival. 61 54
12717266 2003
7
Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. 61 54
11787853 2001
8
Exclusion of SMAD4 mutation as an early genetic change in human pancreatic ductal tumorigenesis. 61 54
11391801 2001
9
Pancreatic intraepithelial neoplasia and infiltrating adenocarcinoma: analysis of progression and recurrence by DPC4 immunohistochemical labeling. 54 61
11431719 2001
10
Heterogeneic distribution of thymidine phosphorylase between primary tumors and metastatic lesions of human pancreatic ductal carcinoma: implications for the efficacy of chemotherapy with 5-FU or its derivatives. 61 54
11391857 2001
11
ACOT4 accumulation via AKT-mediated phosphorylation promotes pancreatic tumourigenesis. 61
33148467 2021
12
Therapeutic Approaches for Metastases from Colorectal Cancer and Pancreatic Ductal Carcinoma. 61
33466892 2021
13
Deep learning analysis for the detection of pancreatic cancer on endosonographic images: a pilot study. 61
32910528 2021
14
[Successful Surgical Resection of Expansive-Growth Acinar Cell Carcinoma-A Case Report]. 61
33468914 2020
15
Malignant solitary fibrous tumor of the pancreas: a case report. 61
33188464 2020
16
Impact of 68Ga-FAPI-PET/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas. 61
33097632 2020
17
Entosis: From Cell Biology to Clinical Cancer Pathology. 61
32883000 2020
18
[Inhibition of Copper Transporter-1 by Ammonium Tetrathiocarbolybdate in the Treatment of Pancreatic Cancer]. 61
32975078 2020
19
EGFR Mutated Lung Adenocarcinoma Metastasis to the Pancreas Mimicking Primary Pancreatic Ductal Carcinoma. 61
32727769 2020
20
Synchronous Primary Pancreatic Ductal Carcinoma and Colonic Adenocarcinoma Present in a Patient With History of Skin Squamous Cell Carcinoma. 61
32620648 2020
21
[Establishment and clinical testing of pancreatic cancer Faster R-CNN AI system based on fast regional convolutional neural network]. 61
32610422 2020
22
High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer. 61
32580737 2020
23
Three cases of follicular pancreatitis: association between radiological findings and pathological features. 61
32577208 2020
24
Tumor budding as a prognostic factor in pancreatic ductal adenocarcinoma. 61
31786688 2020
25
Primary non-ampullary duodenal follicular lymphoma presenting with obstructive jaundice. 61
31401784 2020
26
Fibrosis and cancer: A strained relationship. 61
32147542 2020
27
EZH2 Downregulation Augments the Effect of Irradiation in Reducing Pancreatic Cancer Cell Proliferation in vitro. 61
32161011 2020
28
Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer. 61
31527373 2020
29
Solitary pancreatic metastasis of gastric cancer with synchronous pancreatic ductal carcinoma: A case report. 61
32416485 2020
30
Hsa-MiR-590-3p Promotes the Malignancy Progression of Pancreatic Ductal Carcinoma by Inhibiting the Expression of p27 and PPP2R2A via G1/S Cell Cycle Pathway. 61
33149617 2020
31
NF-κB p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma. 61
31940589 2020
32
Cutaneous Malassezia: Commensal, Pathogen, or Protector? 61
33575223 2020
33
Quantitative dynamic contrast-enhanced MR imaging for the preliminary prediction of the response to gemcitabine-based chemotherapy in advanced pancreatic ductal carcinoma. 61
31743881 2019
34
MCLA-128 Fights NRG1 Fusion-Positive Cancers. 61
31685488 2019
35
PACAP and PAC1 receptor expression in pancreatic ductal carcinoma. 61
31788045 2019
36
Glutamine Anabolism Plays a Critical Role in Pancreatic Cancer by Coupling Carbon and Nitrogen Metabolism. 61
31665640 2019
37
Mutational Patterns in Pancreatic Juice of Intraductal Papillary Mucinous Neoplasms and Concomitant Pancreatic Cancer. 61
31404021 2019
38
Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. 61
31533831 2019
39
The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells. 61
31164413 2019
40
MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with 99mTc(I) Tricarbonyl Complex. 61
31242384 2019
41
ILF2 promotes anchorage independence through direct regulation of PTEN. 61
31423236 2019
42
Targeting PIN1 exerts potent antitumor activity in pancreatic ductal carcinoma via inhibiting tumor metastasis. 61
31148345 2019
43
Evaluation of a biomarker for the diagnosis of pancreas cancer using an animal model. 61
31404387 2019
44
[MicroRNA-21 correlates TGF-β1 pathway of pancreatic ductal adenocarcinoma]. 61
31413212 2019
45
Predictive Factors for Elevated Postoperative Carbohydrate Antigen 19-9 Levels in Patients With Resected Pancreatic Cancer. 61
31177164 2019
46
Mixed ductal-acinar cell carcinoma of the pancreas: A case report. 61
30967946 2019
47
Reduction of intrapancreatic neural density in cancer tissue predicts poorer outcome in pancreatic ductal carcinoma. 61
30776178 2019
48
[A Case Report of Conversion Surgery for Pancreatic Ductal Adenocarcinoma with Liver Metastasis after Chemotherapy]. 61
31164541 2019
49
Genome-wide CRISPR screen reveals PSMA6 to be an essential gene in pancreatic cancer cells. 61
30898113 2019
50
Diabetes of the exocrine pancreas. 61
30151918 2019

Variations for Pancreatic Ductal Carcinoma

Expression for Pancreatic Ductal Carcinoma

Search GEO for disease gene expression data for Pancreatic Ductal Carcinoma.

Pathways for Pancreatic Ductal Carcinoma

Pathways related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 83)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 VEGFA TP53 STAT3 MYC MUC6 MUC5AC
2
Show member pathways
13.85 TP53 STAT3 SMAD4 MYC MUC6 MUC5AC
3
Show member pathways
13.76 VEGFA TYMP TP53 STAT3 SMAD4 MYC
4
Show member pathways
13.74 STAT3 SMAD4 MYC MUC6 MUC5AC MUC2
5
Show member pathways
13.73 VEGFA TYMP TP53 STAT3 SMAD4 MYC
6
Show member pathways
13.56 VEGFA STAT3 SMAD4 KRT7 KRT20 ERBB2
7
Show member pathways
13.55 VEGFA TYMP TP53 STAT3 SMAD4 MYC
8
Show member pathways
13.41 VEGFA TP53 STAT3 MYC MUC1 ERBB2
9
Show member pathways
13.36 TYMP SMAD4 ERBB2 EGFR EGF CXCL12
10
Show member pathways
13.34 VEGFA TYMP ERBB2 EGFR EGF CXCL12
11
Show member pathways
13.13 TYMP TP53 TGM2 EGFR EGF CXCL12
12
Show member pathways
13.12 TP53 STAT3 SMAD4 MYC EGFR EGF
13
Show member pathways
13.05 VEGFA TP53 MYC ERBB2 EGFR EGF
14
Show member pathways
12.99 VEGFA TP53 STAT3 MYC EGFR CXCL12
15 12.81 VEGFA TP53 MYC ERBB2 EGFR EGF
16
Show member pathways
12.77 VEGFA TP53 STAT3 SMAD4 MYC ERBB2
17
Show member pathways
12.7 TP53 STAT3 ERBB2 EGFR EGF CDKN2A
18
Show member pathways
12.69 TP53 SMAD4 MYC MUC2 ERBB2 EGFR
19
Show member pathways
12.65 TP53 STAT3 MYC ERBB2 EGFR
20
Show member pathways
12.62 VEGFA TP53 STAT3 MYC ERBB2 EGFR
21 12.55 VEGFA TP53 STAT3 MYC ERBB2 EGFR
22
Show member pathways
12.47 STAT3 MYC EGFR EGF CXCL12
23
Show member pathways
12.46 TYMP STAT3 ERBB2 EGFR EGF CXCL12
24 12.44 VEGFA ERBB2 EGFR EGF
25 12.42 TP53 SMAD4 MYC CDKN2A CDH1
26 12.42 VEGFA TP53 STAT3 SMAD4 MYC ERBB2
27 12.4 TP53 SMAD4 MYC CDKN2A
28
Show member pathways
12.38 VEGFA TP53 STAT3 SMAD4 MYC MUC1
29
Show member pathways
12.37 TP53 STAT3 ERBB2 EGFR EGF
30
Show member pathways
12.36 VEGFA TP53 STAT3 EGFR
31
Show member pathways
12.33 TYMP TP53 MYC EGFR CXCL12
32 12.33 VEGFA TP53 STAT3 MYC ERBB2 EGFR
33
Show member pathways
12.32 STAT3 MYC MUC1 ERBB2 EGFR EGF
34
Show member pathways
12.3 MUC6 MUC5AC MUC2 MUC1
35 12.24 STAT3 ERBB2 EGFR EGF
36
Show member pathways
12.2 STAT3 MYC ERBB2 EGFR EGF
37
Show member pathways
12.18 MUC6 MUC5AC MUC2 MUC1
38 12.16 VEGFA TP53 SMAD4 MYC EGFR CDH1
39
Show member pathways
12.15 STAT3 SMAD4 EGFR EGF
40 12.13 VEGFA STAT3 MYC EGF
41
Show member pathways
12.12 STAT3 ERBB2 EGFR EGF
42
Show member pathways
12.09 TP53 STAT3 ERBB2 EGFR
43 12.06 TP53 SMAD4 MYC ERBB2 CDKN2A
44 12.05 VEGFA TP53 STAT3 MYC MUC1
45 12.03 TP53 MYC EGFR EGF CDKN2A
46
Show member pathways
12.02 MUC6 MUC5AC MUC2 MUC1
47
Show member pathways
12.02 ERBB2 EGFR EGF CXCL12
48 12.01 VEGFA STAT3 ERBB2 EGFR EGF
49 11.99 STAT3 MYC EGFR EGF
50 11.98 VEGFA TP53 STAT3 SMAD4 MYC EGFR

GO Terms for Pancreatic Ductal Carcinoma

Cellular components related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.81 VEGFA MUC6 MUC5AC MUC2 MUC1 MSLN
2 mucus layer GO:0070701 8.96 MUC5AC MUC2
3 Golgi lumen GO:0005796 8.92 MUC6 MUC5AC MUC2 MUC1

Biological processes related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.15 VEGFA TP53 STAT3 SMAD4 MYC EGFR
2 cytokine-mediated signaling pathway GO:0019221 9.93 VEGFA TP53 STAT3 MYC MUC1
3 positive regulation of protein kinase B signaling GO:0051897 9.88 VEGFA ERBB2 EGFR EGF
4 positive regulation of cell proliferation GO:0008284 9.87 VEGFA STAT3 MYC ERBB2 EGFR EGF
5 positive regulation of cell migration GO:0030335 9.85 VEGFA STAT3 EGFR EGF CXCL12
6 positive regulation of endothelial cell proliferation GO:0001938 9.8 VEGFA EGF CXCL12
7 cellular response to drug GO:0035690 9.79 TP53 MYC EGFR
8 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.78 MUC6 MUC5AC MUC2 MUC1
9 positive regulation of epithelial cell proliferation GO:0050679 9.73 VEGFA MYC ERBB2 EGFR
10 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.72 TP53 STAT3 SMAD4
11 positive regulation of MAP kinase activity GO:0043406 9.71 VEGFA ERBB2 EGFR EGF
12 positive regulation of phosphorylation GO:0042327 9.7 VEGFA EGFR EGF
13 positive regulation of gene expression GO:0010628 9.7 VEGFA TP53 STAT3 MYC ERBB2 EGF
14 regulation of cell motility GO:2000145 9.69 ERBB2 EGFR EGF
15 ERBB2 signaling pathway GO:0038128 9.67 ERBB2 EGFR EGF
16 O-glycan processing GO:0016266 9.67 MUC6 MUC5AC MUC2 MUC1
17 positive regulation of protein localization to early endosome GO:1902966 9.62 VEGFA EGF
18 positive regulation of axon extension involved in axon guidance GO:0048842 9.6 VEGFA CXCL12
19 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.59 TP53 MUC1
20 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.58 VEGFA TP53
21 negative regulation of immature T cell proliferation in thymus GO:0033088 9.57 ERBB2 CDKN2A
22 positive regulation of epithelial tube formation GO:1905278 9.56 VEGFA EGF
23 positive regulation of cell adhesion GO:0045785 9.56 VEGFA TGM2 ERBB2 CXCL12
24 positive regulation of transcription, DNA-templated GO:0045893 9.56 TP53 STAT3 SMAD4 MYC EGFR EGF
25 negative regulation of ERBB signaling pathway GO:1901185 8.8 ERBB2 EGFR EGF

Molecular functions related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.96 VEGFA TYMP TP53 TGM2 STAT3 SMAD4
2 identical protein binding GO:0042802 9.86 VEGFA TP53 TGM2 STAT3 SMAD4 ERBB2
3 p53 binding GO:0002039 9.5 TP53 MUC1 CDKN2A
4 growth factor activity GO:0008083 9.46 VEGFA TYMP EGF CXCL12
5 MDM2/MDM4 family protein binding GO:0097371 9.37 TP53 CDKN2A
6 protein phosphatase binding GO:0019903 8.92 TP53 STAT3 ERBB2 EGFR

Sources for Pancreatic Ductal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....